Drug Type Small molecule drug |
Synonyms Changtuoning, ET, Penehyclidine + [4] |
Mechanism M1 receptor antagonists(Muscarinic acetylcholine receptor M1 antagonists), M3 receptor antagonists(Muscarinic acetylcholine receptor M3 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (24 Oct 2002), |
Regulation- |
Molecular FormulaC20H30ClNO2 |
InChIKeyDDTVVMRZNVIVQM-UHFFFAOYSA-N |
CAS Registry151937-76-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anesthesia | CN | 24 Oct 2002 | |
Drug intoxication | CN | 24 Oct 2002 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Biliary pain | Phase 2 | CN | 19 May 2017 | |
Spasm biliary | Phase 2 | CN | 19 May 2017 | |
Pulmonary Disease, Chronic Obstructive | Phase 2 | CN | 21 Jul 2008 | |
Shock, Septic | Phase 1 | CN | 11 Jun 2012 | |
Parkinson Disease | Phase 1 | CN | 15 Mar 2012 | |
Shock | Phase 1 | CN | 15 Mar 2012 | |
Smooth muscle spasm | Phase 1 | CN | 15 Mar 2012 |
Phase 4 | - | 100 | bbkfhikqnr(bnqhtohhtr) = jvecergykf nxqodhfxzq (cdunjagtpp ) | - | 14 Oct 2022 | ||
TIVA group | bbkfhikqnr(bnqhtohhtr) = xjdvmiuoas nxqodhfxzq (cdunjagtpp ) | ||||||
Phase 3 | - | 864 | qezvenpten(pcciskamqw) = dry mouth and delirium kfhyqodofp (dyncndqhpb ) | Positive | 01 Apr 2022 | ||
Placebo |